Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

NCT06096974 is registered in ClinicalTrials.gov with Shanghai YingLi Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT06096974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06096974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
October 24, 2023
Completion date
April 30, 2026
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors